This histogram enumerates side effects from a completed 2019 Phase 3 trial (NCT04051710) in the Group I (Test) ARM group. Side effects include: Headache with 2%, Anaemia with 1%, Pyrexia with 1%, Asthenia with 0%, Hyperchlorhydria with 0%.
2 Treatment Groups
1 of 2
1 of 2
600 Total Participants · 2 Treatment Groups
Primary Treatment: Test Product · No Placebo Group · N/A
Experimental Group · 1 Intervention: Test Product · Intervention Types: Device
ActiveComparator Group · 1 Intervention: Control Product · Intervention Types: Device
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Screening: ~3 weeks
Reporting: throughout the study. each participating couple will engage in 8 acts over a 4 week period.
Closest Location: Essential Access Health · Berkeley, CA
2020First Recorded Clinical Trial
2 TrialsResearching Sexually Transmitted Diseases
3 CompletedClinical Trials
Age 18 - 65 · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You are willing to use the study products for eight acts of vaginal intercourse within four weeks of study entry.
You do not agree to use any vaginal or sexual lubricant except the product supplied by the study.
You do not agree not to use sex toys or drugs intended to enhance or diminish sexual response when using study condoms.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.